RecruitingNot ApplicableNCT07427537

Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients

Sponsor

University Hospital, Clermont-Ferrand

Enrollment

90 participants

Start Date

Jan 29, 2026

Study Type

INTERVENTIONAL

Conditions

Colon Neoplasm Cancer, Lung Neuropathy;Peripheral

Summary

This study aims to find out whether certain molecules in the blood, called microRNAs, are linked to how often and how severely people develop nerve damage from chemotherapy. The investigators will look at patients receiving cancer drugs known to affect the nerves, such as paclitaxel (used for lung cancer) and oxaliplatin (used for colorectal cancer).

Eligibility

Min Age: 18 Years

Inclusion Criteria2

Patient treated for colorectal cancer and scheduled to receive oxaliplatin-based adjuvant chemotherapy for at least 6 cycles, or
Patient treated for lung cancer and scheduled to receive paclitaxel-based chemotherapy for at least 4 cycles.

Exclusion Criteria6

Neurodegenerative disease (e.g., Parkinson's, Alzheimer's, etc.),
History of stroke,
Pre-existing neuropathy (QLQ-CIPN20 sensory score ≥ 15/100),
Pain (NRS ≥ 4/10),
Pregnant or breastfeeding women,
Patients under guardianship, curatorship, deprived of liberty, or under legal protection